Medeon Biodesign, Inc. (6499.TWO) Stock

About Medeon Biodesign, Inc.

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

Medeon Biodesign, Inc. is led by CEO Yu Te Chang, employs 1,496 people, headquartered in Taipei, TW, publicly traded since 2014.

Medeon Biodesign, Inc. (6499.TWO) stock trades at $82.20 with a market capitalization of $7.97B. The stock is valued at a price-to-earnings (P/E) ratio of 27.86, price-to-book of 6.48, price-to-sales of 18.62. Over the past 52 weeks the stock has ranged between $55.80 and $134.00, and currently trades 38.7% below its 52-week high.

On profitability, Medeon Biodesign, Inc. generates a return on equity (ROE) of -51.16% (negative, reflecting a net loss), an operating margin of -131.56%, a net profit margin of -130.48%.

Official website: www.medeonbiodesign.com

Medeon Biodesign, Inc. (6499.TWO) — frequently asked questions